Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand

Implications for vaccine development

Deborah A. Williamson, Pierre R. Smeesters, Andrew C. Steer, Julie Morgan, Mark Davies, Philip Carter, Arlo Upton, Steven Tong, John Fraser, Nicole J. Moreland

    Research output: Contribution to journalArticleResearchpeer-review

    4 Downloads (Pure)

    Abstract

    Background: Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are responsible for a significant disease burden amongst Maori and Pacific populations in New Zealand (NZ). However, contemporary data are lacking regarding circulating group A Streptococcal (GAS) strains in NZ. Such information is important in guiding vaccine development. 

    Methods: GAS isolates from April to June 2015 were recovered from skin and pharyngeal samples from children living in areas of high social deprivation in Auckland, NZ, a significant proportion of which are Maori or Pacific. These children are among the highest risk group for developing ARF. Isolates were compared to concurrently collected pharyngeal isolates from Dunedin, NZ, where both the proportion of Maori and Pacific children and risk of developing ARF is low. Emm typing, emm cluster typing and theoretical coverage of the 30-valent vaccine candidate were undertaken as previously described. 

    Results: A high diversity of emm types and a high proportion of emm-pattern D and cluster D4 isolates were detected amongst both skin and pharyngeal isolates in children at high risk of ARF. Pharyngeal isolates from children at low risk of ARF within the same country were significantly less diverse, less likely to be emm pattern D, and more likely to be theoretically covered by the 30-valent M protein vaccine. 

    Conclusions: The high proportion of emm pattern D GAS strains amongst skin and pharyngeal isolates from children at high risk of ARF raises further questions about the role of skin infection in ARF pathogenesis. Emm types and emm clusters differed considerably between ARF endemic and non-endemic settings, even within the same country. This difference should be taken into account for vaccine development.

    Original languageEnglish
    Article number561
    Pages (from-to)1-7
    Number of pages7
    JournalBMC Infectious Diseases
    Volume16
    DOIs
    Publication statusPublished - 12 Oct 2016

    Fingerprint

    Rheumatic Fever
    Pharyngitis
    Streptococcus pyogenes
    New Zealand
    Vaccines
    Skin
    Infection
    Proteins
    Rheumatic Heart Disease

    Cite this

    Williamson, Deborah A. ; Smeesters, Pierre R. ; Steer, Andrew C. ; Morgan, Julie ; Davies, Mark ; Carter, Philip ; Upton, Arlo ; Tong, Steven ; Fraser, John ; Moreland, Nicole J. / Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand : Implications for vaccine development. In: BMC Infectious Diseases. 2016 ; Vol. 16. pp. 1-7.
    @article{6b8c7a412dab45a8a68d76a9020bcc60,
    title = "Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development",
    abstract = "Background: Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are responsible for a significant disease burden amongst Maori and Pacific populations in New Zealand (NZ). However, contemporary data are lacking regarding circulating group A Streptococcal (GAS) strains in NZ. Such information is important in guiding vaccine development. Methods: GAS isolates from April to June 2015 were recovered from skin and pharyngeal samples from children living in areas of high social deprivation in Auckland, NZ, a significant proportion of which are Maori or Pacific. These children are among the highest risk group for developing ARF. Isolates were compared to concurrently collected pharyngeal isolates from Dunedin, NZ, where both the proportion of Maori and Pacific children and risk of developing ARF is low. Emm typing, emm cluster typing and theoretical coverage of the 30-valent vaccine candidate were undertaken as previously described. Results: A high diversity of emm types and a high proportion of emm-pattern D and cluster D4 isolates were detected amongst both skin and pharyngeal isolates in children at high risk of ARF. Pharyngeal isolates from children at low risk of ARF within the same country were significantly less diverse, less likely to be emm pattern D, and more likely to be theoretically covered by the 30-valent M protein vaccine. Conclusions: The high proportion of emm pattern D GAS strains amongst skin and pharyngeal isolates from children at high risk of ARF raises further questions about the role of skin infection in ARF pathogenesis. Emm types and emm clusters differed considerably between ARF endemic and non-endemic settings, even within the same country. This difference should be taken into account for vaccine development.",
    author = "Williamson, {Deborah A.} and Smeesters, {Pierre R.} and Steer, {Andrew C.} and Julie Morgan and Mark Davies and Philip Carter and Arlo Upton and Steven Tong and John Fraser and Moreland, {Nicole J.}",
    year = "2016",
    month = "10",
    day = "12",
    doi = "10.1186/s12879-016-1891-6",
    language = "English",
    volume = "16",
    pages = "1--7",
    journal = "BMC Infectious Diseases",
    issn = "1471-2334",
    publisher = "BioMed Central",

    }

    Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand : Implications for vaccine development. / Williamson, Deborah A.; Smeesters, Pierre R.; Steer, Andrew C.; Morgan, Julie; Davies, Mark; Carter, Philip; Upton, Arlo; Tong, Steven; Fraser, John; Moreland, Nicole J.

    In: BMC Infectious Diseases, Vol. 16, 561, 12.10.2016, p. 1-7.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand

    T2 - Implications for vaccine development

    AU - Williamson, Deborah A.

    AU - Smeesters, Pierre R.

    AU - Steer, Andrew C.

    AU - Morgan, Julie

    AU - Davies, Mark

    AU - Carter, Philip

    AU - Upton, Arlo

    AU - Tong, Steven

    AU - Fraser, John

    AU - Moreland, Nicole J.

    PY - 2016/10/12

    Y1 - 2016/10/12

    N2 - Background: Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are responsible for a significant disease burden amongst Maori and Pacific populations in New Zealand (NZ). However, contemporary data are lacking regarding circulating group A Streptococcal (GAS) strains in NZ. Such information is important in guiding vaccine development. Methods: GAS isolates from April to June 2015 were recovered from skin and pharyngeal samples from children living in areas of high social deprivation in Auckland, NZ, a significant proportion of which are Maori or Pacific. These children are among the highest risk group for developing ARF. Isolates were compared to concurrently collected pharyngeal isolates from Dunedin, NZ, where both the proportion of Maori and Pacific children and risk of developing ARF is low. Emm typing, emm cluster typing and theoretical coverage of the 30-valent vaccine candidate were undertaken as previously described. Results: A high diversity of emm types and a high proportion of emm-pattern D and cluster D4 isolates were detected amongst both skin and pharyngeal isolates in children at high risk of ARF. Pharyngeal isolates from children at low risk of ARF within the same country were significantly less diverse, less likely to be emm pattern D, and more likely to be theoretically covered by the 30-valent M protein vaccine. Conclusions: The high proportion of emm pattern D GAS strains amongst skin and pharyngeal isolates from children at high risk of ARF raises further questions about the role of skin infection in ARF pathogenesis. Emm types and emm clusters differed considerably between ARF endemic and non-endemic settings, even within the same country. This difference should be taken into account for vaccine development.

    AB - Background: Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are responsible for a significant disease burden amongst Maori and Pacific populations in New Zealand (NZ). However, contemporary data are lacking regarding circulating group A Streptococcal (GAS) strains in NZ. Such information is important in guiding vaccine development. Methods: GAS isolates from April to June 2015 were recovered from skin and pharyngeal samples from children living in areas of high social deprivation in Auckland, NZ, a significant proportion of which are Maori or Pacific. These children are among the highest risk group for developing ARF. Isolates were compared to concurrently collected pharyngeal isolates from Dunedin, NZ, where both the proportion of Maori and Pacific children and risk of developing ARF is low. Emm typing, emm cluster typing and theoretical coverage of the 30-valent vaccine candidate were undertaken as previously described. Results: A high diversity of emm types and a high proportion of emm-pattern D and cluster D4 isolates were detected amongst both skin and pharyngeal isolates in children at high risk of ARF. Pharyngeal isolates from children at low risk of ARF within the same country were significantly less diverse, less likely to be emm pattern D, and more likely to be theoretically covered by the 30-valent M protein vaccine. Conclusions: The high proportion of emm pattern D GAS strains amongst skin and pharyngeal isolates from children at high risk of ARF raises further questions about the role of skin infection in ARF pathogenesis. Emm types and emm clusters differed considerably between ARF endemic and non-endemic settings, even within the same country. This difference should be taken into account for vaccine development.

    UR - http://www.scopus.com/inward/record.url?scp=84991215019&partnerID=8YFLogxK

    U2 - 10.1186/s12879-016-1891-6

    DO - 10.1186/s12879-016-1891-6

    M3 - Article

    VL - 16

    SP - 1

    EP - 7

    JO - BMC Infectious Diseases

    JF - BMC Infectious Diseases

    SN - 1471-2334

    M1 - 561

    ER -